Drug intelligence / Profile preview

LiveSpo Navax Kid

Development stage: Unknown
Lead developer: LiveSpo Pharma
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intranasal

Overview

LiveSpo Navax Kid is a probiotic nasal spray containing spores of *Bacillus subtilis* and *Bacillus clausii* at a concentration of 0.6 billion spores per mL. Developed by LiveSpo Pharma, it is designed to prevent acute respiratory infections (ARIs) in children by maintaining respiratory and throat hygiene and potentially reducing the risk of bacterial co-infections. The product aims to support the immune system and reduce reliance on antibiotics by populating the nasal mucosa with beneficial bacteria. It has been evaluated in clinical trials in Vietnam for its efficacy in reducing the incidence and duration of respiratory disease episodes in healthy preschool children.

Brand names: LiveSpo Navax Kid
Other names: LiveSpo Navax Kid

Beyond the preview

Go deeper on LiveSpo Navax Kid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiveSpo Navax Kid.

Explore the full profile